Inhaled AAT
Antitrypsin Deficiency lung disease
Alpha-1 Deficiency
Alpha-1 Antitrypsin Deficiency (AATD) is a rare genetic condition that increases the risk for lung disease, liver disorders, and panniculitis (a skin disease).
Alpha-1 Antitrypsin is a protein produced in the liver and also in other organs such as the lung. Its main role is to protect the lung from being damaged during inflammation.
People with low levels of Alpha-1 Antitrypsin may be at risk of developing
a severe chronic lung disease.
To learn more about Alpha-1 Antitrypsin Deficiency, please visit the Alpha-1 Foundation website at:
https://www.alpha1.org
AAT by inhalation
Administration of AAT by inhalation aims to replace the deficient Alpha-1 Antitrypsin protein in the lung.
Inhalation is a convenient, non-invasive and widely used therapeutic approach to deliver medicines directly to the lungs.
Inhaled-AAT is an investigational
medicine. This means that it is not
yet approved for marketing and can
only be given within a clinical study.
Kamada has conducted several clinical studies with Inhaled-AAT. More than 200 patients have received Inhaled-AAT in clinical research settings.